220 related articles for article (PubMed ID: 34536044)
1. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
[TBL] [Abstract][Full Text] [Related]
2. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
3. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
4. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
5. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
6. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
7. Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.
Matos AI; Peres C; Carreira B; Moura LIF; Acúrcio RC; Vogel T; Wegener E; Ribeiro F; Afonso MB; Santos FMF; Martínez-Barriocanal Á; Arango D; Viana AS; Góis PMP; Silva LC; Rodrigues CMP; Graca L; Jordan R; Satchi-Fainaro R; Florindo HF
Adv Sci (Weinh); 2023 Sep; 10(25):e2300299. PubMed ID: 37434063
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
9. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
10. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
11. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane.
Li Y; Zhang H; Wang R; Wang Y; Li R; Zhu M; Zhang X; Zhao Z; Wan Y; Zhuang J; Zhang H; Huang X
Adv Mater; 2023 Mar; 35(13):e2208923. PubMed ID: 36715052
[TBL] [Abstract][Full Text] [Related]
12. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
13. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
[TBL] [Abstract][Full Text] [Related]
15. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
16. Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors.
Wang T; Han M; Han Y; Jiang Z; Zheng Q; Zhang H; Li Z
ACS Nano; 2024 Feb; 18(8):6333-6347. PubMed ID: 38349234
[TBL] [Abstract][Full Text] [Related]
17. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
18. Peptide nanovaccine in melanoma immunotherapy.
Dehghankhold M; Sadat Abolmaali S; Nezafat N; Mohammad Tamaddon A
Int Immunopharmacol; 2024 Mar; 129():111543. PubMed ID: 38301413
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
[TBL] [Abstract][Full Text] [Related]
20. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Chen J; Fang H; Hu Y; Wu J; Zhang S; Feng Y; Lin L; Tian H; Chen X
Bioact Mater; 2022 Jan; 7():167-180. PubMed ID: 34466725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]